News
-
-
PRESS RELEASE
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
NanoViricides, Inc. announces successful safety and tolerability results of broad-spectrum antiviral drug NV-387 in juvenile animal model study, paving the way for pediatric clinical trials -
-
PRESS RELEASE
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
NanoViricides reports progress in Phase IIA Ebola Treatment Clinical Trial for NV-387 Oral Gummies, evaluating dosage regimens and efficacy against Ebola Bundibugyo virus, with safety and tolerability focus -
-
PRESS RELEASE
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
NanoViricides, Inc. provides details on Phase II Clinical Trial of NV-387 Oral Gummies for treating Bundibugyo Ebolavirus (BDBV) outbreak in DRC. Trial targets optimal dosing regimen and safety signals for Ebola Virus Disease patients -
-
PRESS RELEASE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
NanoViricides, Inc. reports filing the Annual Report on Form 10-K with SEC showcasing achievements including Phase II trials for NV-387, an antiviral drug for Mpox and Ebola. Financials and milestones are detailed -
-
PRESS RELEASE
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
NanoViricides, Inc. starts enrolling patients in Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebolavirus in DRC. Trial aims for safe dosing protocol and efficacy evaluation for Ebola virus infection
